TriangleGallium Ga 68-DOTATATE (NCT04082520)
Gallium Ga 68-DOTATATE trial for Grade 1 Meningioma (NCT04082520). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with progressive meningioma after radiation, without a safe further radiation option or curative surgery option. A DOTATATE PET scan must show sufficient somatostatin-receptor uptake. Grade 1 and grade 2–3 tumors are assessed separately.
The idea: Lutathera binds somatostatin receptors and delivers radioactive lutetium to those cells. Patients receive up to four infusions, eight weeks apart, with scans, blood tests and questionnaires. Researchers assess six-month disease control and toxicity. Optic-nerve-sheath and extracranial meningiomas are excluded.
This phase 2 study plans 42 patients. Kenneth Merrell leads Mayo’s recruiting Rochester site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.